Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors.

chemotherapy nasopharyngeal carcinoma quality of life radiotherapy survivorship toxicity unmet needs

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 03 01 2020
accepted: 12 05 2020
entrez: 30 6 2020
pubmed: 1 7 2020
medline: 1 7 2020
Statut: epublish

Résumé

Concerted research efforts over the last three decades have resulted in improved survival and outcomes for patients diagnosed with nasopharyngeal carcinoma (NPC). The evolution of radiotherapy techniques has facilitated improved dose delivery to target volumes while reducing dose to the surrounding normal tissue, improving both disease control and quality of life (QoL). In parallel, clinical trials focusing on determining the optimal systemic therapy to use in conjunction with radiotherapy have been largely successful, resulting in improved locoregional, and distant control. As a consequence, neoadjuvant chemotherapy (NACT) prior to definitive chemoradiotherapy has recently emerged as the preferred standard for patients with locally advanced NPC. Two of the major challenges in interpreting toxicity and QoL data from the published literature have been the reliance on: (1) clinician rather than patient reported outcomes; and (2) reporting statistical rather than clinical meaningful differences in measures. Despite the lower rates of toxicity that have been achieved with highly conformal radiotherapy techniques, survivors remain at moderate risk of persistent and long-lasting treatment effects, and the development of late radiation toxicities such as hearing loss, cranial neuropathies and cognitive impairment many years after successful treatment can herald a significant decline in QoL. Future approaches to reduce long-term toxicity will rely on: (1) identifying individual patients most likely to benefit from NACT; (2) development of response-adapted radiation strategies following NACT; and (3) anticipated further dose reductions to organs at risk with proton and particle therapy. With increasing numbers of survivors, many in the prime of their adult life, research to identify, and strategies to address the unmet needs of NPC survivors are required. This contemporary review will summarize our current knowledge of long-term toxicity, QoL and unmet needs of this survivorship group.

Identifiants

pubmed: 32596155
doi: 10.3389/fonc.2020.00930
pmc: PMC7303258
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

930

Informations de copyright

Copyright © 2020 McDowell, Corry, Ringash and Rischin.

Références

Support Care Cancer. 2009 Aug;17(8):1117-28
pubmed: 19319577
J Clin Endocrinol Metab. 2011 Aug;96(8):2330-40
pubmed: 21613351
Radiother Oncol. 2001 Dec;61(3):287-97
pubmed: 11730999
Strahlenther Onkol. 2003 Jan;179(1):21-30
pubmed: 12540981
Radiother Oncol. 2014 Mar;110(3):377-84
pubmed: 24630534
Radiother Oncol. 2017 Jun;123(3):394-400
pubmed: 28532605
Int J Cancer. 2019 Jul 1;145(1):295-305
pubmed: 30613964
Curr Treat Options Oncol. 2018 Jul 9;19(8):44
pubmed: 29987676
Head Neck. 2019 May;41(5):1282-1289
pubmed: 30548091
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):541-546
pubmed: 28581395
BMC Cancer. 2015 Oct 15;15:709
pubmed: 26472233
Head Neck. 2001 Feb;23(2):113-25
pubmed: 11303628
Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12
pubmed: 9253778
Onco Targets Ther. 2017 Jul 06;10:3329-3336
pubmed: 28740408
N Engl J Med. 2019 Sep 19;381(12):1124-1135
pubmed: 31150573
Cancer J. 2006 Mar-Apr;12(2):147-54
pubmed: 16630406
Psychooncology. 2014 Oct;23(10):1185-91
pubmed: 24729515
Radiother Oncol. 2014 Mar;110(3):416-21
pubmed: 23953411
Strahlenther Onkol. 2016 Dec;192(12):931-943
pubmed: 27761611
J Clin Oncol. 2002 Apr 1;20(7):1845-52
pubmed: 11919243
J Clin Oncol. 2011 Jan 1;29(1):89-96
pubmed: 21098316
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):952-60
pubmed: 25832687
J Clin Oncol. 1988 Sep;6(9):1401-10
pubmed: 3047335
J Cancer. 2019 Aug 28;10(21):5057-5064
pubmed: 31602257
Radiat Oncol. 2016 Sep 26;11(1):127
pubmed: 27671196
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):836-844
pubmed: 30954521
Radiother Oncol. 2018 Jan;126(1):25-36
pubmed: 29153464
Qual Life Res. 2007 Feb;16(1):65-74
pubmed: 17033899
Oral Oncol. 2019 Jan;88:180-185
pubmed: 30616792
Head Neck. 2016 Jul;38(7):1097-103
pubmed: 26894614
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Otolaryngol Head Neck Surg. 2015 Sep 18;44:38
pubmed: 26385356
BMC Cancer. 2014 Nov 21;14:856
pubmed: 25413127
PLoS One. 2018 Mar 22;13(3):e0194733
pubmed: 29566078
J Natl Cancer Inst. 2003 Aug 6;95(15):1110-7
pubmed: 12902440
Head Neck. 2016 Apr;38 Suppl 1:E1026-32
pubmed: 26041548
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):567-580
pubmed: 31276776
Exp Neurol. 2020 Feb;324:113118
pubmed: 31756316
Radiother Oncol. 2010 Nov;97(2):263-9
pubmed: 20817290
Cancer. 2003 Apr 15;97(8):2019-26
pubmed: 12673733
Br J Radiol. 2016 Sep;89(1065):20150621
pubmed: 27376590
Radiother Oncol. 2019 Feb;131:179-185
pubmed: 30279047
Head Neck. 2019 Oct;41(10):3516-3524
pubmed: 31313419
Radiat Oncol. 2008 Jan 24;3:4
pubmed: 18218078
Head Neck. 2016 Apr;38 Suppl 1:E1886-95
pubmed: 26705956
Radiol Med. 2017 Apr;122(4):303-308
pubmed: 28070838
J Clin Oncol. 1999 Mar;17(3):1008-19
pubmed: 10071296
JAMA Oncol. 2018 Dec 1;4(12):1791-1792
pubmed: 30383125
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):574-580
pubmed: 28581397
Radiother Oncol. 2012 Sep;104(3):286-93
pubmed: 22995588
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e47-54
pubmed: 23122981
Health Psychol. 2010 Jan;29(1):65-71
pubmed: 20063937
Psychooncology. 2019 Dec;28(12):2295-2306
pubmed: 31654540
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):373-82
pubmed: 18337023
Radiother Oncol. 2019 Aug;137:9-15
pubmed: 31048235
J Clin Oncol. 2015 Jan 10;33(2):156-64
pubmed: 25488965
Cancer. 2017 Nov 1;123(21):4147-4157
pubmed: 28662313
Cancer. 2007 Jan 15;109(2):313-21
pubmed: 17154159
Cancer Med. 2019 Nov;8(16):6887-6893
pubmed: 31560840
Eur J Cancer. 2017 Apr;75:150-158
pubmed: 28235726
Oral Oncol. 2013 Jan;49(1):49-54
pubmed: 22892236
JAMA Otolaryngol Head Neck Surg. 2019 Jun 13;:
pubmed: 31194229
Oral Oncol. 2009 Jul;45(7):555-61
pubmed: 19028135
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1397-402
pubmed: 20044215
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):134-145
pubmed: 31568813
J Clin Oncol. 2004 Sep 1;22(17):3485-90
pubmed: 15337796
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Oral Oncol. 2013 May;49(5):468-74
pubmed: 23369852
Eur J Cancer. 2005 Jan;41(2):280-7
pubmed: 15661554
Oral Oncol. 2012 Oct;48(10):1045-1050
pubmed: 22633108
Radiother Oncol. 2012 Sep;104(3):324-30
pubmed: 22236614
Radiother Oncol. 2012 Aug;104(2):205-12
pubmed: 22883107
Radiother Oncol. 2006 Aug;80(2):263-7
pubmed: 16916557
Oncotarget. 2017 Jul 11;8(28):46211-46218
pubmed: 28515352
J Oncol. 2018 Aug 6;2018:3625302
pubmed: 30174692
Eur J Cancer. 2008 Sep;44(13):1793-8
pubmed: 18599286
Strahlenther Onkol. 2012 Mar;188(3):282-6
pubmed: 22314578
Eur J Cancer. 2017 Apr;75:14-23
pubmed: 28214653
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1238-44
pubmed: 11955734
Radiother Oncol. 2016 Feb;118(2):244-50
pubmed: 26705681
J Clin Oncol. 2007 Nov 1;25(31):4873-9
pubmed: 17971582
J Clin Oncol. 2009 Jan 10;27(2):242-9
pubmed: 19064973
Psychol Health Med. 2017 Apr;22(4):449-461
pubmed: 27687515
Lancet Oncol. 2012 Feb;13(2):163-71
pubmed: 22154591
Med Oncol. 2013 Dec;30(4):710
pubmed: 23999842
Lancet Oncol. 2015 Jun;16(6):645-55
pubmed: 25957714
Arch Otolaryngol Head Neck Surg. 2008 Mar;134(3):241-8
pubmed: 18347247
J Natl Cancer Inst. 2019 May 1;111(5):490-497
pubmed: 30239887
PLoS One. 2012;7(6):e36529
pubmed: 22701557
J Clin Oncol. 2010 Jun 20;28(18):2996-3001
pubmed: 20479390
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):589-96
pubmed: 18793962
J Radiat Res. 2018 Jul 1;59(4):446-455
pubmed: 29750261
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):722-6
pubmed: 20044217
Cancer. 2002 Feb 15;94(4):1012-7
pubmed: 11920470
Radiother Oncol. 2018 Jan;126(1):37-42
pubmed: 28864073
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1421-7
pubmed: 20605344
Cancer. 2000 Feb 15;88(4):900-11
pubmed: 10679661
Radiother Oncol. 2019 Sep;138:93-98
pubmed: 31252300
Curr Oncol. 2015 Jun;22(3):e142-7
pubmed: 26089724
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56
pubmed: 16377415
J Natl Cancer Inst. 2010 Aug 4;102(15):1188-98
pubmed: 20634482
Oncotarget. 2017 Feb 21;8(8):14029-14038
pubmed: 28152511
Semin Radiat Oncol. 2018 Jan;28(1):64-74
pubmed: 29173757
Head Neck. 2017 Feb;39(2):E23-E28
pubmed: 27704653
Head Neck. 2016 Apr;38 Suppl 1:E925-33
pubmed: 25994561
Ann Oncol. 2018 Mar 1;29(3):731-736
pubmed: 29236943
Ann Oncol. 2012 Feb;23(2):427-35
pubmed: 21525406
Lancet Oncol. 2016 Nov;17(11):1509-1520
pubmed: 27686945
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):420-8
pubmed: 20452132
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):340-352
pubmed: 30191868
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1590-1591
pubmed: 30063942
Ann Oncol. 2018 Sep 1;29(9):1972-1979
pubmed: 30016391
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):356-64
pubmed: 18355980
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):28-34
pubmed: 17765405
J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70
pubmed: 22056739
Cancer. 2001 Oct 15;92(8):2126-35
pubmed: 11596029
Cancer Res Treat. 2019 Apr;51(2):685-695
pubmed: 30121968
J Clin Oncol. 2005 Sep 20;23(27):6730-8
pubmed: 16170180
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):981-91
pubmed: 17145528

Auteurs

Lachlan McDowell (L)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.

June Corry (J)

GenesisCare Radiation Oncology, Division Radiation Oncology, St. Vincent's Hospital, Melbourne, VIC, Australia.
Department of Medicine St Vincent's, The University of Melbourne, Melbourne, VIC, Australia.

Jolie Ringash (J)

Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, ON, Canada.

Danny Rischin (D)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Classifications MeSH